<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; color: #000000; font-weight: bold;">As filed with the Securities and Exchange Commission on March 7, 2025</div>
    <div style="text-align: right; color: #000000; font-weight: bold;">Registration No. 333-</div>
    <div style="text-align: center; color: #000000;"><br>
    </div>
    <div style="text-align: center; color: #000000;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">SENTI BIOSCIENCES, INC.</div>
    <div style="text-align: center; color: #000000;">(Exact name of registrant as specified in its charter)</div>
    <div style="text-align: center; color: #000000;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z97dda22dc955404fa0340d494aa0a0eb" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-weight: bold;">Delaware</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-weight: bold;">2 Corporate Drive, First Floor</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">South San Francisco, CA 94080</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Telephone: (650) 382-3281</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-weight: bold;">86-2437900</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">(IRS Employer Identification No.)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Senti Biosciences, Inc. Amended and Restated 2022 Equity Incentive Plan</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Senti Biosciences, Inc. 2022 Amended and Restated Inducement Plan</div>
    <div style="text-align: center; color: #000000;">(Full title of the plans)</div>
    <div style="text-align: center; color: #000000;"> <br>
    </div>
    <div style="text-align: center; color: #000000;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 100%; color: #000000;"></div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Timothy Lu, M.D., Ph.D</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Chief Executive Officer</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Senti Biosciences, Inc.</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">2 Corporate Drive, First Floor</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">South San Francisco, CA 94080</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Telephone: (650) 239-2030</div>
    <div style="text-align: center; color: #000000;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
    <div style="text-align: center; color: #000000;"> <br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 100%; color: #000000; text-align: center;"></div>
    <br>
    <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">Copies to:</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Jocelyn M. Arel</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Maggie Wong</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Goodwin Procter LLP</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">620 Eighth Avenue</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">New York, NY 10018</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">(212) 813-8800</div>
    <div style="color: #000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated
      filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z15b9f3f2b7bc4f2083f1651dc9bc1431" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Large accelerated filer &#9744;</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: right; color: rgb(0, 0, 0);">Accelerated filer &#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Non-accelerated filer &#9746;</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: right; color: #000000;">Smaller reporting company &#9746;</div>
            <div style="text-align: right; color: #000000;">Emerging growth company &#9746;</div>
          </td>
        </tr>

    </table>
    <div style="color: #000000;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
      7(a)(2)(B) of the Securities Act. &#9746;</div>
    <div style="color: rgb(0, 0, 0);"><br>
    </div>
    <div style="text-align: center; color: #000000; font-size: 12pt;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt;"></font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION E</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: #000000;">This Registration Statement on Form S-8 (this &#8220;Registration Statement&#8221;) is being filed by Senti Biosciences, Inc. (the &#8220;Company&#8221;) to register a total of 4,541,472 shares of common stock, par value $0.0001
      per share (the &#8220;Common Stock&#8221;), reserved and available for issuance under the Senti Biosciences, Inc. Amended and Restated 2022 Equity Incentive Plan (the &#8220;A&amp;R 2022 Plan&#8221;), which amended and restated the Senti Biosciences, Inc. 2022 Equity
      Incentive Plan, 48,294 additional shares of Common Stock, reserved for issuance under the Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan (the &#8220;2022 ESPP&#8221;) and 500,000 additional shares of Common Stock, reserved for issuance under the Senti
      Biosciences, Inc. Amended and Restated 2022 Inducement Plan (the &#8220;A&amp;R Inducement Plan&#8221;). On January 27, 2025, the Company filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Company&#8217;s definitive proxy statement for the 2025 Special
      Stockholders&#8217; Meeting (the &#8220;Special Meeting&#8221;) held on March 6, 2025 for the purpose of, among other things, approving a proposal to adopt the A&amp;R 2022 Plan. The A&amp;R 2022 Plan, as proposed, increases the number of shares of Common Stock
      reserved for issuance under the A&amp;R 2022 Plan by 4,300,000 shares. The proposal to adopt the A&amp;R 2022 Plan was approved by the Company&#8217;s stockholders on March 6, 2025 at the Special Meeting. This Registration Statement registers (i) 4,300,000
      additional shares of Common Stock available for issuance under the A&amp;R 2022 Plan, (ii) 241,472 shares of Common Stock that were added to the A&amp;R 2022 Plan on January 1, 2025 pursuant to the annual automatic increase provision in the A&amp;R
      2022 Plan,(iii) 48,294 shares of Common Stock that were added to the 2022 ESPP on January 1, 2025 pursuant to the annual automatic increase provision in the 2022 ESPP and (iv) 500,000 additional shares of Common Stock available for issuance under the
      A&amp;R Inducement Plan.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="color: #000000;">Pursuant to General Instruction E for Form S-8 regarding Registration of Additional Securities, the contents of the Registration Statements on Form S-8 File No. 333-266958, File No.
        333-269816 and File No. 333-276459, filed with the SEC on </font>August 18, 2022<font style="color: rgb(0, 0, 0);">, </font>February 16, 2023<font style="color: rgb(0, 0, 0);"> and </font>January 10, 2024<font style="color: rgb(0, 0, 0);">,
        respectively, are hereby incorporated by reference in this Registration Statement to the extent not replaced hereby.</font></div>
    <div>&#160;</div>
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PART I</div>
    </div>
    <div>
      <div>&#160;</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</div>
    </div>
    <div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z97513c7a38414f2da2cea8731f257fcc" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; color: #000000; font-weight: bold;">Item 1.</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: #000000; font-weight: bold;">Plan Information.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div><br>
      </div>
      <div style="color: #000000;">The documents containing the information specified in this Item 1 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In accordance
        with the rules and regulations of the SEC and the instructions to Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the
        Securities Act.</div>
    </div>
    <div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="za98c3a48b56442c4bb7f0ea89ef59958" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; color: #000000; font-weight: bold;">Item 2.</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: #000000; font-weight: bold;">Registrant Information and Employee Plan Annual Information.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div><br>
      </div>
      <div style="color: #000000;">The documents containing the information specified in this Item 2 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the SEC and
        the instructions to Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.</div>
      <div>&#160;</div>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">PART II</div>
    <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z369cc611831a4390a5b9d98c0f62314a" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; color: #000000; font-weight: bold;">Item 3.</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: #000000; font-weight: bold;">Incorporation of Documents by Reference.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
    </div>
    <div>
      <div style="color: #000000;">The registrant hereby incorporates by reference into this Registration Statement the following documents filed with the SEC:</div>
      <div><br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z5017b479f2d84e3b8b91597bbfd6f458" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top;">(a)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Annual Report on Form 10-K for the year ended <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000029/snti-20231231.htm">December 31, 2023</a>, filed by the registrant with the SEC on March 21, 2024, as
              amended by the Amendment No. 1 on Form 10-K/A, filed by the registrant with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000037/snti-20231231.htm">April 26, 2024</a> (other than information
              furnished rather than filed);</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="za446df575c17402b9821b422c126c0ad" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top;">(b)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Quarterly reports on Form 10-Q for the quarterly periods ended <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000052/snti-20240331.htm">March 31, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000101/snti-20240630.htm">June 30, 2024</a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000116/snti-20240930.htm">September




                30, 2024</a>, as filed with the SEC on May 9, 2024, August 13, 2024 and November 14, 2024, respectively.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z9ddf2922c75c442ba91c60284a18aba3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top;">(c)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000005/snti-20240103.htm">January 5, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000022/snti-20240206.htm">February 6, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000036/snti-20240423.htm">April
                26, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000041/snti-20240426.htm">May 2, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000061/snti-20240514.htm">May 17, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000081/snti-20240710.htm">July 12,
                2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000091/snti-20240716.htm">July 16, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000094/snti-20240717.htm">July 17, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000099/snti-20240813.htm">August 13,
                2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000105/snti-20240923.htm">September 27, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427024000108/snti-20241022.htm">October 25, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000114036124048184/ef20039400_8k.htm">December
                2, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000114036124048293/ef20039439_8k.htm">December 3, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000114036125000337/ef20040800_8k.htm">January 6, 2025</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000162828025004293/snti-20250131.htm">February
                6, 2025</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000185427025000008/snti-20250223.htm">February 25, 2025</a>; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z3ecbc45d620241c58acc1772e29eb256" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top;">(d)</td>
          <td style="width: auto; vertical-align: top;">
            <div>The description of the registrant&#8217;s <font style="color: rgb(0, 0, 0);">Common Stock</font> contained in the registrant&#8217;s Registration Statement on Form 8-A (File No. 001-40440), filed by the registrant with the SEC under Section 12(b) of
              the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), on <a href="https://www.sec.gov/Archives/edgar/data/1854270/000119312521171915/d174490d8a12b.htm">May 25, 2021</a>, including any amendments or reports filed for the
              purpose of updating such description.</div>
          </td>
        </tr>

    </table>
    <div>
      <div><br>
      </div>
      <div style="color: #000000;">All documents that the registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates
        that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the
        filing of such documents.</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="color: #000000;">Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently
        filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of
        this Registration Statement.</div>
      <div>&#160;</div>
      <div style="color: #000000;">Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.</div>
      <div>&#160;</div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z1bb67f3afc124cd9bb7bb55ebf311408" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 4.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description of Securities.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
    <div>
      <div style="color: #000000;">Not applicable.</div>
      <div>&#160;</div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z4f74b089f88243c491324e1f44b11dfb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 5.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Interests of Named Experts and Counsel.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
    <div>
      <div style="color: #000000;">Not applicable.</div>
      <div>&#160;</div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z25935cef48cb4d17a1b486d69f934b6c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 6.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Indemnification of Directors and Officers.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Our Second Amended and Restated Certificate of Incorporation, as amended and / or restated from time to time (the &#8220;Certificate of Incorporation&#8221;) provides that all of our directors,
      officers, employees and agents shall be entitled to be indemnified by us to the fullest extent permitted by Section 145 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). Section 145 of the DGCL concerning indemnification of officers, directors,
      employees and agents is set forth below.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Section 145. Indemnification of officers, directors, employees and agents; insurance.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z0af4786e1ae64f268bdc3d3fa4400edb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
              administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
              corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and
              reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with
              respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo
              contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and,
              with respect to any criminal action or proceeding, had reasonable cause to believe that the person&#8217;s conduct was unlawful.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z26b272f2d6a946b4b81af0806030473b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to
              procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
              another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement&#160; of such action or suit if the
              person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which
              such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the
              adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z38d4b76ad5314f69b97237e304e68c94" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">To the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a) and (b) of
              this section, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z432d0e87105a4cf68d55bb6dc7858732" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Any indemnification under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification
              of the present or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and (b) of this section. Such determination shall be made,
              with respect to a person who is a director or officer at the time of such determination, (1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (2) by a committee of
              such directors designated by majority vote of such directors, even though less than a quorum, or (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion, or (4) by the
              stockholders.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6ff19322ddab44c8be69c2916364c01e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(e)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Expenses (including attorneys&#8217; fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of
              the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified
              by the corporation as authorized in this section. Such expenses (including attorneys&#8217; fees) incurred by former officers and directors or other employees and agents may be so paid upon such terms and conditions, if any, as the corporation
              deems appropriate.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z240e0e74be4b4eb6aa1df59b0e101936" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(f)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">The indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not be deemed exclusive of any other rights to which those seeking
              indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity and as to action in another capacity
              while holding such office. A right to indemnification or to advancement of expenses arising under a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to such provision after the
              occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the
              time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z33b266c22eed42b09921eb0b6525f81e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(g)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">A corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
              corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or
              arising out of such person&#8217;s status as such, whether or not the corporation would have the power to indemnify such person against such liability under this section.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zda16b88e5ca64aaf9a23552a3efc9af2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(h)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">For purposes of this section, references to &#8220;the corporation&#8221; shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a
              consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent
              of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the
              same position under this section with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zec30fc732c36457ea75b3f974a35dd57" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(i)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">For purposes of this section, references to &#8220;other enterprises&#8221; shall include employee benefit plans; references to &#8220;fines&#8221; shall include any excise taxes assessed on a person with respect to any employee
              benefit plan; and references to &#8220;serving at the request of the corporation&#8221; shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer,
              employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of
              an employee benefit plan shall be deemed to have acted in a manner &#8220;not opposed to the best interests of the corporation&#8221; as referred to in this section.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb0de007feb824e4ea5006752bd7a06b5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(j)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">The indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a
              director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb7a2ad0877a24d4081b171c65d92699e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: #000000;">(k)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">The Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification brought under this section or under any by law, agreement,
              vote of stockholders or disinterested directors, or otherwise. The Court of Chancery may summarily determine a corporation&#8217;s obligation to advance expenses (including attorneys&#8217; fees).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions,
      or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
      liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
      the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public
      policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">In accordance with Section 102(b)(7) of the DGCL, our Certificate of Incorporation provides that no director or officer shall be personally liable to us or any of our stockholders for
      monetary damages resulting from breaches of their fiduciary duty as directors or officers, except to the extent such limitation on or exemption from liability is not permitted under the DGCL. The effect of this provision of our Certificate of
      Incorporation is to eliminate our rights and those of our stockholders (through stockholders&#8217; derivative suits on our behalf) to recover monetary damages against a director or officer for breach of the fiduciary duty of care as a director or officer,
      including breaches resulting from negligent or grossly negligent behavior, except, as restricted by Section 102(b)(7) of the DGCL. However, this provision does not limit or eliminate our rights or the rights of any stockholder to seek non-monetary
      relief, such as an injunction or rescission, in the event of a breach of a director&#8217;s or officer&#8217;s duty of care.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">If the DGCL is amended to authorize corporate action further eliminating or limiting the liability of directors or officers, then, in accordance with our Certificate of Incorporation,
      the liability of our directors or officers to us or our stockholders will be eliminated or limited to the fullest extent authorized by the DGCL, as so amended. Any repeal or amendment of provisions of our Certificate of Incorporation limiting or
      eliminating the liability of directors or officers, whether by our stockholders or by changes in law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent
      such amendment or change in law permits us to further limit or eliminate the liability of directors or officers on a retroactive basis.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Our Certificate of Incorporation also provides that we will, to the fullest extent authorized or permitted by applicable law, indemnify our current and former officers and directors,
      as well as those persons who, while directors or officers of our corporation, are or were serving as directors, officers, employees or agents of another entity, trust or other enterprise, including service with respect to an employee benefit plan, in
      connection with any threatened, pending or completed proceeding, whether civil, criminal, administrative or investigative, against all expense, liability and loss (including, without limitation, attorney&#8217;s fees, judgments, fines, ERISA excise taxes
      and penalties and amounts paid in settlement) reasonably incurred or suffered by any such person in connection with any such proceeding.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Notwithstanding the foregoing, a person eligible for indemnification pursuant to our Certificate of Incorporation will be indemnified by us in connection with a proceeding initiated
      by such person only if such proceeding was authorized by our Board, except for proceedings to enforce rights to indemnification.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">The right to indemnification which is conferred by our Certificate of Incorporation is a contract right that includes the right to be paid by us the expenses incurred in defending or
      otherwise participating in any proceeding referenced above in advance of its final disposition, provided, however, that if the DGCL requires, an advancement of expenses incurred by our officer or director (solely in the capacity as an officer or
      director of our corporation) will be made only upon delivery to us of an undertaking, by or on behalf of such officer or director, to repay all amounts so advanced if it is ultimately determined that such person is not entitled to be indemnified for
      such expenses under our Certificate of Incorporation or otherwise.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">The rights to indemnification and advancement of expenses will not be deemed exclusive of any other rights which any person covered by our Certificate of Incorporation may have or
      hereafter acquire under law, our Certificate of Incorporation, our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), an agreement, vote of stockholders or disinterested directors, or otherwise.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Any repeal or amendment of provisions of our Certificate of Incorporation affecting indemnification rights, whether by our stockholders or by changes in law, or the adoption of any
      other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis, and will not in
      any way diminish or adversely affect any right or protection existing at the time of such repeal or amendment or adoption of such inconsistent provision with respect to any act or omission occurring prior to such repeal or amendment or adoption of
      such inconsistent provision. Our Certificate of Incorporation will also permit us, to the extent and in the manner authorized or permitted by law, to indemnify and to advance expenses to persons other that those specifically covered by our
      Certificate of Incorporation.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Our Bylaws include the provisions relating to advancement of expenses and indemnification rights consistent with those which are set forth in our Certificate of Incorporation. In
      addition, our Bylaws provide for a right of indemnity to bring a suit in the event a claim for indemnification or advancement of expenses is not paid in full by us within a specified period of time. Our Bylaws also permit us to purchase and maintain
      insurance, at our expense, to protect us and/or any director, officer, employee or agent of our corporation or another entity, trust or other enterprise against any expense, liability or loss, whether or not we would have the power to indemnify such
      person against such expense, liability or loss under the DGCL.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Any repeal or amendment of provisions of our Bylaws affecting indemnification rights, whether by our Board, stockholders or by changes in applicable law, or the adoption of any other
      provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis, and will not in any way
      diminish or adversely affect any right or protection existing thereunder with respect to any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">We have entered into indemnification agreements with each of our officers and directors, a form of which is filed as Exhibit 10.5 to our Registration Statement on Form S-4 that was
      declared effective by the SEC on May 13, 2022. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses
      incurred as a result of any proceeding against them as to which they could be indemnified.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or
      rescission.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; color: #000000;">Pursuant to that certain Business Combination Agreement, dated as of December 19, 2021, as amended or modified from time to time, including as amended by Amendment No. 1 to Business
      Combination Agreement, dated as of February 12, 2022 and Amendment No. 2, dated as of May 19, 2022, in each case, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc. and us, we agreed to continue to indemnify DYNS&#8217; directors and
      officers and have agreed to the continuation of director and officer liability insurance covering such directors and officers.</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zb7e315b861ed49ec8936567b971e21e7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 7.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Exemption from Registration Claimed.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
    <div>
      <div style="color: #000000;">Not applicable.</div>
      <div><br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zdb114ddceca34bc29c370241414af927" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibits.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="ze79eb39921824f9b89debd6d66869e3a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1854270/000119312522174498/d360749dex31.htm">4.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Second Amended and Restated Certificate of Incorporation of the registrant (incorporated by reference from Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on June 15,
              2022).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1854270/000185427024000081/a202407128kex31.htm">4.2</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Senti Biosciences, Inc. (Officer Exculpation Amendment) (incorporated by reference from Exhibit
              3.1 to the current report on Form 8-K filed with the SEC on July 12, 2024).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1854270/000185427024000094/a202407178kex31.htm">4.3</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Senti Biosciences, Inc. (Reverse Stock Split Amendment) (incorporated by reference from Exhibit
              3.1 to the current report on Form 8-K filed with the SEC on July 17, 2024).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1854270/000119312522174498/d360749dex32.htm">4.4</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Amended and Restated Bylaws of the registrant (incorporated by reference from Exhibit 3.2 to the current report on Form 8-K filed with the SEC on June 15, 2022).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="ef20045051_ex5-1.htm">5.1*</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Opinion of Goodwin Procter LLP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div style="text-align: center;"><a href="ef20045051_ex23-1.htm">23.1*</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Consent of KPMG LLP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="ef20045051_ex5-1.htm">23.2*</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Consent of Goodwin Procter LLP (included in Exhibit 5.1).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="#POWEROFATTORNEYANDSIGNATU">24.1*</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Power of Attorney (included on signature page of this Registration Statement).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="ef20045051_ex99-1.htm">99.1*</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Senti Biosciences, Inc. Amended and Restated 2022 Equity Incentive Plan and forms of award agreements thereunder.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1854270/000185427022000019/a6302210qex104.htm">99.2</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q, filed
              with the SEC on August 15, 2022).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="ef20045051_ex99-3.htm">99.3*</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Senti Biosciences Inc. Amended and Restated 2022 Inducement Plan and forms of award agreements thereunder.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="ef20045051_ex107.htm">107*</a></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Filing Fee Table</div>
          </td>
        </tr>

    </table>
    <div style="color: #000000;"><br>
      <hr noshade="noshade" align="left" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto 0px 0px; height: 2px; width: 15%; color: #000000;"></div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z4611598eaf974dba9a0fb2e021b39101" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left;">*</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div>Filed herewith.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z367f146e84b846d1b3052edaa29da1c7" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 9.</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">Undertakings.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <div style="color: #000000;">(a) The undersigned registrant hereby undertakes:</div>
    </div>
    <div>
      <div>&#160;</div>
      <div style="color: #000000;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div>
      <div>&#160;</div>
      <div style="color: #000000;">(i) To include any prospectus required by Section 10(a)(3) of the Securities Act.</div>
      <div>&#160;</div>
      <div style="color: #000000;">(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent
        a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
        was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
        no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration Statement.</div>
      <div>&#160;</div>
      <div style="color: #000000;">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.</div>
      <div>&#160;</div>
      <div style="color: #000000;"><font style="font-style: italic;">Provided, however</font>, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is
        contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.</div>
      <div style="color: #000000;"> <br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div style="color: #000000;">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the
        offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
      <div>&#160;</div>
      <div style="color: #000000;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
      <div>&#160;</div>
      <div style="color: #000000;">(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the
        Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration
        Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
    </div>
    <div>&#160;</div>
    <div style="color: #000000;">(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the
      registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
      (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
      person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
      indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
      caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, CA on the 7th day of March, 2025.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="za723469e3d004984b5b4806fd955ed2e" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">SENTI BIOSCIENCES, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Timothy Lu</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Timothy Lu, M.D., Ph.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Chief Executive Officer (Principal Executive Officer)</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;"><a name="POWEROFATTORNEYANDSIGNATU"><!--Anchor--></a>POWER OF ATTORNEY AND SIGNATURES</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Timothy Lu as such person&#8217;s true and lawful attorney-in-fact and agent with full
      power of substitution and resubstitution, for such person in such person&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file
      the same, with all exhibits thereto, and all documents in connection therewith, with the SEC granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done
      in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do
      or cause to be done by virtue hereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z2653f3c1efc64434a2118f5602f1cafe" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 21%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Signature</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 60%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title</div>
          </td>
          <td style="width: 2%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0);">/s/ Timothy Lu</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 60%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: #000000;">Chief Executive Officer and Director</div>
            <div style="text-align: center; color: #000000;">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</div>
          </td>
          <td style="width: 2%; vertical-align: top;" rowspan="2" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">March 7, 2025</div>
          </td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Timothy Lu, M.D., Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0);">/s/ Fran Schulz</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 60%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;" rowspan="2" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">March 7, 2025</div>
          </td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Fran Schulz</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0);">/s/ Brenda Cooperstone</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 60%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;" rowspan="2" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">March 7, 2025</div>
          </td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Brenda Cooperstone, M.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0);">/s/ Edward Mathers</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 60%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;" rowspan="2" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">March 7, 2025</div>
          </td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Edward Mathers</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0);">/s/ James J. Collins</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 60%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;" rowspan="2" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">March 7, 2025</div>
          </td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">James J. (Jim) Collins, Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0);">/s/ Donald Tang</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 60%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;" rowspan="2" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: top;" rowspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0);">March 7, 2025</div>
          </td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Donald Tang</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0);">/s/ Feng Hsiung</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Director</div>
          </td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">
            <div style="text-align: center; color: #000000;">March 7, 2025</div>
          </td>
        </tr>
        <tr>
          <td style="width: 21%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Feng Hsiung</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 60%; vertical-align: middle;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "ef20045051_s8.htm", "description": "S-8", "secsgml_size_bytes": 86557}]
{"company-data": {"conformed-name": "Senti Biosciences, Inc.", "cik": "0001854270", "assigned-sic": "2836", "organization-name": "03 Life Sciences", "irs-number": "862437900", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-285655", "film-number": "25721267"}, "business-address": {"street1": "2 CORPORATE DRIVE, FIRST FLOOR", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "(650) 382-3281"}, "mail-address": {"street1": "2 CORPORATE DRIVE, FIRST FLOOR", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080"}, "former-company": [{"former-conformed-name": "Senti Biosciences, Inc.\\", "date-changed": "20220615"}, {"former-conformed-name": "Dynamics Special Purpose Corp.", "date-changed": "20210331"}]}
As filed with the Securities and Exchange Commission on March 7, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
SENTI BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
2 Corporate Drive, First Floor
South San Francisco, CA 94080
Telephone: (650) 382-3281
86-2437900
(IRS Employer Identification No.)
Senti Biosciences, Inc. Amended and Restated 2022 Equity Incentive Plan
Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan
Senti Biosciences, Inc. 2022 Amended and Restated Inducement Plan
(Full title of the plans)
Timothy Lu, M.D., Ph.D
Chief Executive Officer
Senti Biosciences, Inc.
2 Corporate Drive, First Floor
South San Francisco, CA 94080
Telephone: (650) 239-2030
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Jocelyn M. Arel
Maggie Wong
Goodwin Procter LLP
620 Eighth Avenue
New York, NY 10018
(212) 813-8800
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated
      filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
      7(a)(2)(B) of the Securities Act. ☒
REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION E
This Registration Statement on Form S-8 (this "Registration Statement") is being filed by Senti Biosciences, Inc. (the "Company") to register a total of 4,541,472 shares of common stock, par value $0.0001
      per share (the "Common Stock"), reserved and available for issuance under the Senti Biosciences, Inc. Amended and Restated 2022 Equity Incentive Plan (the "A&R 2022 Plan"), which amended and restated the Senti Biosciences, Inc. 2022 Equity
      Incentive Plan, 48,294 additional shares of Common Stock, reserved for issuance under the Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan (the "2022 ESPP") and 500,000 additional shares of Common Stock, reserved for issuance under the Senti
      Biosciences, Inc. Amended and Restated 2022 Inducement Plan (the "A&R Inducement Plan"). On January 27, 2025, the Company filed with the Securities and Exchange Commission (the "SEC"), the Company's definitive proxy statement for the 2025 Special
      Stockholders' Meeting (the "Special Meeting") held on March 6, 2025 for the purpose of, among other things, approving a proposal to adopt the A&R 2022 Plan. The A&R 2022 Plan, as proposed, increases the number of shares of Common Stock
      reserved for issuance under the A&R 2022 Plan by 4,300,000 shares. The proposal to adopt the A&R 2022 Plan was approved by the Company's stockholders on March 6, 2025 at the Special Meeting. This Registration Statement registers (i) 4,300,000
      additional shares of Common Stock available for issuance under the A&R 2022 Plan, (ii) 241,472 shares of Common Stock that were added to the A&R 2022 Plan on January 1, 2025 pursuant to the annual automatic increase provision in the A&R
      2022 Plan,(iii) 48,294 shares of Common Stock that were added to the 2022 ESPP on January 1, 2025 pursuant to the annual automatic increase provision in the 2022 ESPP and (iv) 500,000 additional shares of Common Stock available for issuance under the
      A&R Inducement Plan.
Pursuant to General Instruction E for Form S-8 regarding Registration of Additional Securities, the contents of the Registration Statements on Form S-8 File No. 333-266958, File No.
        333-269816 and File No. 333-276459, filed with the SEC on
August 18, 2022
,
February 16, 2023
and
January 10, 2024
,
        respectively, are hereby incorporated by reference in this Registration Statement to the extent not replaced hereby.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1.
Plan Information.
The documents containing the information specified in this Item 1 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act"). In accordance
        with the rules and regulations of the SEC and the instructions to Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the
        Securities Act.
Item 2.
Registrant Information and Employee Plan Annual Information.
The documents containing the information specified in this Item 2 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the SEC and
        the instructions to Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.
PART II
Item 3.
Incorporation of Documents by Reference.
The registrant hereby incorporates by reference into this Registration Statement the following documents filed with the SEC:
(a)
Annual Report on Form 10-K for the year ended
December 31, 2023
, filed by the registrant with the SEC on March 21, 2024, as
              amended by the Amendment No. 1 on Form 10-K/A, filed by the registrant with the SEC on
April 26, 2024
(other than information
              furnished rather than filed);
(b)
Quarterly reports on Form 10-Q for the quarterly periods ended
March 31, 2024
,
June 30, 2024
, and
September

                30, 2024
, as filed with the SEC on May 9, 2024, August 13, 2024 and November 14, 2024, respectively.
(c)
Current Reports on Form 8-K filed with the SEC on
January 5, 2024
,
February 6, 2024
,
April
                26, 2024
,
May 2, 2024
,
May 17, 2024
,
July 12,
                2024
,
July 16, 2024
,
July 17, 2024
,
August 13,
                2024
,
September 27, 2024
,
October 25, 2024
,
December
                2, 2024
,
December 3, 2024
,
January 6, 2025
,
February
                6, 2025
,
February 25, 2025
; and
(d)
The description of the registrant's
Common Stock
contained in the registrant's Registration Statement on Form 8-A (File No. 001-40440), filed by the registrant with the SEC under Section 12(b) of
              the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on
May 25, 2021
, including any amendments or reports filed for the
              purpose of updating such description.
All documents that the registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates
        that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the
        filing of such documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently
        filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of
        this Registration Statement.
Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
Not applicable.
Item 6.
Indemnification of Directors and Officers.
Our Second Amended and Restated Certificate of Incorporation, as amended and / or restated from time to time (the "Certificate of Incorporation") provides that all of our directors,
      officers, employees and agents shall be entitled to be indemnified by us to the fullest extent permitted by Section 145 of the Delaware General Corporation Law (the "DGCL"). Section 145 of the DGCL concerning indemnification of officers, directors,
      employees and agents is set forth below.
Section 145. Indemnification of officers, directors, employees and agents; insurance.
(a)
A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
              administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
              corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and
              reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with
              respect to any criminal action or proceeding, had no reasonable cause to believe the person's conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo
              contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and,
              with respect to any criminal action or proceeding, had reasonable cause to believe that the person's conduct was unlawful.
(b)
A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to
              procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
              another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement  of such action or suit if the
              person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which
              such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the
              adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.
(c)
To the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a) and (b) of
              this section, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection therewith.
(d)
Any indemnification under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification
              of the present or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and (b) of this section. Such determination shall be made,
              with respect to a person who is a director or officer at the time of such determination, (1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (2) by a committee of
              such directors designated by majority vote of such directors, even though less than a quorum, or (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion, or (4) by the
              stockholders.
(e)
Expenses (including attorneys' fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of
              the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified
              by the corporation as authorized in this section. Such expenses (including attorneys' fees) incurred by former officers and directors or other employees and agents may be so paid upon such terms and conditions, if any, as the corporation
              deems appropriate.
(f)
The indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not be deemed exclusive of any other rights to which those seeking
              indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person's official capacity and as to action in another capacity
              while holding such office. A right to indemnification or to advancement of expenses arising under a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to such provision after the
              occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the
              time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.
(g)
A corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
              corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or
              arising out of such person's status as such, whether or not the corporation would have the power to indemnify such person against such liability under this section.
(h)
For purposes of this section, references to "the corporation" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a
              consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent
              of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the
              same position under this section with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued.
(i)
For purposes of this section, references to "other enterprises" shall include employee benefit plans; references to "fines" shall include any excise taxes assessed on a person with respect to any employee
              benefit plan; and references to "serving at the request of the corporation" shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer,
              employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of
              an employee benefit plan shall be deemed to have acted in a manner "not opposed to the best interests of the corporation" as referred to in this section.
(j)
The indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a
              director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.
(k)
The Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification brought under this section or under any by law, agreement,
              vote of stockholders or disinterested directors, or otherwise. The Court of Chancery may summarily determine a corporation's obligation to advance expenses (including attorneys' fees).
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions,
      or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
      liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
      the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public
      policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
In accordance with Section 102(b)(7) of the DGCL, our Certificate of Incorporation provides that no director or officer shall be personally liable to us or any of our stockholders for
      monetary damages resulting from breaches of their fiduciary duty as directors or officers, except to the extent such limitation on or exemption from liability is not permitted under the DGCL. The effect of this provision of our Certificate of
      Incorporation is to eliminate our rights and those of our stockholders (through stockholders' derivative suits on our behalf) to recover monetary damages against a director or officer for breach of the fiduciary duty of care as a director or officer,
      including breaches resulting from negligent or grossly negligent behavior, except, as restricted by Section 102(b)(7) of the DGCL. However, this provision does not limit or eliminate our rights or the rights of any stockholder to seek non-monetary
      relief, such as an injunction or rescission, in the event of a breach of a director's or officer's duty of care.
If the DGCL is amended to authorize corporate action further eliminating or limiting the liability of directors or officers, then, in accordance with our Certificate of Incorporation,
      the liability of our directors or officers to us or our stockholders will be eliminated or limited to the fullest extent authorized by the DGCL, as so amended. Any repeal or amendment of provisions of our Certificate of Incorporation limiting or
      eliminating the liability of directors or officers, whether by our stockholders or by changes in law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent
      such amendment or change in law permits us to further limit or eliminate the liability of directors or officers on a retroactive basis.
Our Certificate of Incorporation also provides that we will, to the fullest extent authorized or permitted by applicable law, indemnify our current and former officers and directors,
      as well as those persons who, while directors or officers of our corporation, are or were serving as directors, officers, employees or agents of another entity, trust or other enterprise, including service with respect to an employee benefit plan, in
      connection with any threatened, pending or completed proceeding, whether civil, criminal, administrative or investigative, against all expense, liability and loss (including, without limitation, attorney's fees, judgments, fines, ERISA excise taxes
      and penalties and amounts paid in settlement) reasonably incurred or suffered by any such person in connection with any such proceeding.
Notwithstanding the foregoing, a person eligible for indemnification pursuant to our Certificate of Incorporation will be indemnified by us in connection with a proceeding initiated
      by such person only if such proceeding was authorized by our Board, except for proceedings to enforce rights to indemnification.
The right to indemnification which is conferred by our Certificate of Incorporation is a contract right that includes the right to be paid by us the expenses incurred in defending or
      otherwise participating in any proceeding referenced above in advance of its final disposition, provided, however, that if the DGCL requires, an advancement of expenses incurred by our officer or director (solely in the capacity as an officer or
      director of our corporation) will be made only upon delivery to us of an undertaking, by or on behalf of such officer or director, to repay all amounts so advanced if it is ultimately determined that such person is not entitled to be indemnified for
      such expenses under our Certificate of Incorporation or otherwise.
The rights to indemnification and advancement of expenses will not be deemed exclusive of any other rights which any person covered by our Certificate of Incorporation may have or
      hereafter acquire under law, our Certificate of Incorporation, our Amended and Restated Bylaws (the "Bylaws"), an agreement, vote of stockholders or disinterested directors, or otherwise.
Any repeal or amendment of provisions of our Certificate of Incorporation affecting indemnification rights, whether by our stockholders or by changes in law, or the adoption of any
      other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis, and will not in
      any way diminish or adversely affect any right or protection existing at the time of such repeal or amendment or adoption of such inconsistent provision with respect to any act or omission occurring prior to such repeal or amendment or adoption of
      such inconsistent provision. Our Certificate of Incorporation will also permit us, to the extent and in the manner authorized or permitted by law, to indemnify and to advance expenses to persons other that those specifically covered by our
      Certificate of Incorporation.
Our Bylaws include the provisions relating to advancement of expenses and indemnification rights consistent with those which are set forth in our Certificate of Incorporation. In
      addition, our Bylaws provide for a right of indemnity to bring a suit in the event a claim for indemnification or advancement of expenses is not paid in full by us within a specified period of time. Our Bylaws also permit us to purchase and maintain
      insurance, at our expense, to protect us and/or any director, officer, employee or agent of our corporation or another entity, trust or other enterprise against any expense, liability or loss, whether or not we would have the power to indemnify such
      person against such expense, liability or loss under the DGCL.
Any repeal or amendment of provisions of our Bylaws affecting indemnification rights, whether by our Board, stockholders or by changes in applicable law, or the adoption of any other
      provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis, and will not in any way
      diminish or adversely affect any right or protection existing thereunder with respect to any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision.
We have entered into indemnification agreements with each of our officers and directors, a form of which is filed as Exhibit 10.5 to our Registration Statement on Form S-4 that was
      declared effective by the SEC on May 13, 2022. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses
      incurred as a result of any proceeding against them as to which they could be indemnified.
These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or
      rescission.
Pursuant to that certain Business Combination Agreement, dated as of December 19, 2021, as amended or modified from time to time, including as amended by Amendment No. 1 to Business
      Combination Agreement, dated as of February 12, 2022 and Amendment No. 2, dated as of May 19, 2022, in each case, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc. and us, we agreed to continue to indemnify DYNS' directors and
      officers and have agreed to the continuation of director and officer liability insurance covering such directors and officers.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
EXHIBIT INDEX
Exhibit No.
Description
4.1
Second Amended and Restated Certificate of Incorporation of the registrant (incorporated by reference from Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on June 15,
              2022).
4.2
Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Senti Biosciences, Inc. (Officer Exculpation Amendment) (incorporated by reference from Exhibit
              3.1 to the current report on Form 8-K filed with the SEC on July 12, 2024).
4.3
Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Senti Biosciences, Inc. (Reverse Stock Split Amendment) (incorporated by reference from Exhibit
              3.1 to the current report on Form 8-K filed with the SEC on July 17, 2024).
4.4
Amended and Restated Bylaws of the registrant (incorporated by reference from Exhibit 3.2 to the current report on Form 8-K filed with the SEC on June 15, 2022).
5.1*
Opinion of Goodwin Procter LLP.
23.1*
Consent of KPMG LLP.
23.2*
Consent of Goodwin Procter LLP (included in Exhibit 5.1).
24.1*
Power of Attorney (included on signature page of this Registration Statement).
99.1*
Senti Biosciences, Inc. Amended and Restated 2022 Equity Incentive Plan and forms of award agreements thereunder.
99.2
Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q, filed
              with the SEC on August 15, 2022).
99.3*
Senti Biosciences Inc. Amended and Restated 2022 Inducement Plan and forms of award agreements thereunder.
107*
Filing Fee Table
*
Filed herewith.
Item 9.
Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act.
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent
        a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
        was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
        no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement.
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
Provided, however
, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is
        contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the
        offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
        Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration
        Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the
      registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
      (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
      person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
      indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
      caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, CA on the 7th day of March, 2025.
SENTI BIOSCIENCES, INC.
By:
/s/ Timothy Lu
Name:
Timothy Lu, M.D., Ph.D.
Title:
Chief Executive Officer (Principal Executive Officer)
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Timothy Lu as such person's true and lawful attorney-in-fact and agent with full
      power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file
      the same, with all exhibits thereto, and all documents in connection therewith, with the SEC granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done
      in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do
      or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.
Signature
Title
Date
/s/ Timothy Lu
Chief Executive Officer and Director
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
March 7, 2025
Timothy Lu, M.D., Ph.D.
/s/ Fran Schulz
Director
March 7, 2025
Fran Schulz
/s/ Brenda Cooperstone
Director
March 7, 2025
Brenda Cooperstone, M.D.
/s/ Edward Mathers
Director
March 7, 2025
Edward Mathers
/s/ James J. Collins
Director
March 7, 2025
James J. (Jim) Collins, Ph.D.
/s/ Donald Tang
Director
March 7, 2025
Donald Tang
/s/ Feng Hsiung
Director
March 7, 2025
Feng Hsiung